BACKGROUND: @entity157 has an overall 5-year survival of less than 5%. Similarly, @entity788 has a mortality: incidence ratio of 0.99. The aim of this study was to determine the prevalence of @entity1722 and @entity2467 ( @entity2467 ) overexpression and to identify a possible predictive role in @entity1 with these two @entity5 . MATERIALS AND METHODS: We performed a retrospective study on archival specimens of subjects with hepatocellular and @entity3123 . @entity1722 and @entity2467 overexpression were evaluated by immunohistochemistry. RESULTS: Thirty-three @entity1 with @entity3123 and 25 @entity1 with @entity157 were identified. The mean age was 71.7 years for @entity1 with @entity3123 and 66 years for @entity1 with @entity157 . Two @entity1 with @entity157 and none with @entity788 overexpressed @entity1722 , while 2 @entity1 with @entity3123 and 1 @entity1 with @entity157 overexpressed @entity2467 . CONCLUSION: @entity1722 and @entity2467 are not significantly overexpressed in either @entity5 . There appears to be no role for the use of trastuzumab in either @entity5 . Similarly, while there appears to be no role for @entity669 kinase inhibitors in the treatment of @entity157 , further larger studies are necessary in pancreatic @entity420 .

@entity1722 and @entity2467 ( XXXX ) overexpression in hepatocellular and @entity3123 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancy', 'malignancies'] @entity2467 :: ('3815', 'Gene') :: ['c-kit', 'CD117'] @entity157 :: ('MESH:D006528', 'Disease') :: ['Hepatocellular carcinoma', 'hepatocellular carcinoma'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1722 :: ('2064', 'Gene') :: ['HER-2/neu']
@entity2467 :: (3815,Gene) :: ['C-kit']
